| MeSH term | MeSH ID | Detail |
|---|---|---|
| Mandibular Diseases | D008336 | 5 associated lipids |
| Bone Resorption | D001862 | 7 associated lipids |
| Foreign-Body Reaction | D005549 | 10 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Bone Neoplasms | D001859 | 5 associated lipids |
| Fractures, Bone | D050723 | 4 associated lipids |
| Osteoarthritis | D010003 | 4 associated lipids |
| Carcinoma | D002277 | 18 associated lipids |
| Osteonecrosis | D010020 | 5 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Haynes DR et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. | 2001 | Rheumatology (Oxford) | pmid:11426018 |
| Smith MD | Comment on review on T cells in bone biology. | 2004 | Rheumatology (Oxford) | pmid:15448222 |
| Castellino G et al. | The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? | 2010 | Rheumatology (Oxford) | pmid:20299382 |
| Engvall IL et al. | Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. | 2013 | Rheumatology (Oxford) | pmid:23275387 |
| Huang CH et al. | Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. | 2011 | Rheumatology (Oxford) | pmid:20974615 |
| Haynes DR et al. | Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. | 2003 | Rheumatology (Oxford) | pmid:12509625 |
| Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
| Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
| Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
| Naumnik W et al. | Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15638385 |
| Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
| Gurban CV and Mederle O | The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. | 2011 | Rom J Morphol Embryol | pmid:22119834 |
| Takayanagi H | [Crosstalk between the immune and skeletal system]. | 2003 | Ryumachi | pmid:14598653 |
| Mohamed GB and Abdel-Latif EA | Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. | 2011 | Saudi J Kidney Dis Transpl | pmid:21912025 |
| Stenman UH et al. | Prognostic value of serum markers for prostate cancer. | 2005 | Scand J Urol Nephrol Suppl | pmid:16019759 |
| Hosbond SE et al. | Osteoprotegerin as a marker of atherosclerosis: a systematic update. | 2012 | Scand. Cardiovasc. J. | pmid:22506827 |
| Yilmaz Y et al. | Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. | 2010 | Scand. J. Clin. Lab. Invest. | pmid:20942739 |
| Grauslund J et al. | Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? | 2010 | Scand. J. Clin. Lab. Invest. | pmid:20205614 |
| Bjerre M et al. | Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. | 2014 | Scand. J. Clin. Lab. Invest. | pmid:25026506 |
| Sennels HP et al. | Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17852826 |
| Knudsen ST et al. | Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17365993 |
| Altinova AE et al. | Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. | 2011 | Scand. J. Clin. Lab. Invest. | pmid:21486111 |
| Muñoz-Calvo MT et al. | Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. | 2007 | Scand. J. Clin. Lab. Invest. | pmid:17558893 |
| Reenaers C et al. | Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. | 2008 | Scand. J. Gastroenterol. | pmid:18942021 |
| Gehrke T et al. | Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. | 2003 | Scand. J. Rheumatol. | pmid:14690142 |
| Spelling P et al. | Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? | 2008 Nov-Dec | Scand. J. Rheumatol. | pmid:18802807 |
| Sennels H et al. | Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. | 2008 Jul-Aug | Scand. J. Rheumatol. | pmid:18612923 |
| Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
| Hope S et al. | Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. | 2013 | Schizophr. Res. | pmid:23403415 |
| Dieset I et al. | Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. | 2012 | Schizophr. Res. | pmid:22817875 |
| Zang L et al. | The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis. | 2015 | Sci Rep | pmid:26671549 |
| Schiro A et al. | Elevated levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-β are associated with unstable asymptomatic carotid plaques. | 2015 | Sci Rep | pmid:26564003 |
| Mizuno M et al. | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease. | 2015 | Sci Rep | pmid:26561427 |
| Nemeth ZK et al. | Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. | 2015 | Sci Rep | pmid:26459001 |
| Wang B et al. | Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone. | 2015 | Sci Rep | pmid:26329493 |
| Kao SY and Stankovic KM | Transactivation of human osteoprotegerin promoter by GATA-3. | 2015 | Sci Rep | pmid:26216189 |
| Warren JT et al. | Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. | 2014 | Sci Signal | pmid:25140055 |
| Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
| Wickelgren I | Mining the genome for drugs. | 1999 | Science | pmid:10475849 |
| Yang X et al. | Effects of TGF-β1 on OPG/RANKL expression of cementoblasts and osteoblasts are similar without stress but different with mechanical compressive stress. | 2015 | ScientificWorldJournal | pmid:25685846 |
| Zhang Q et al. | Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. | 2013 | ScientificWorldJournal | pmid:24222748 |
| Yasuda H | [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. | 2000 | Seikagaku | pmid:10967683 |
| Takayanagi H | [Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. | 2003 | Seikagaku | pmid:14748148 |
| Schlieper G et al. | Inhibitors of calcification in blood and urine. | 2007 Mar-Apr | Semin Dial | pmid:17374084 |
| Daoussis D et al. | Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. | 2010 | Semin. Arthritis Rheum. | pmid:19095294 |
| Josson S et al. | Tumor-stroma co-evolution in prostate cancer progression and metastasis. | 2010 | Semin. Cell Dev. Biol. | pmid:19948237 |
| Wang AY | Consequences of chronic inflammation in peritoneal dialysis. | 2011 | Semin. Nephrol. | pmid:21439430 |
| Hruska KA et al. | Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. | 2004 | Semin. Nephrol. | pmid:14730507 |
| Hortobagyi GN | Novel approaches to the management of bone metastases. | 2003 | Semin. Oncol. | pmid:14613037 |
| Berenson JR | Advances in the biology and treatment of myeloma bone disease. | 2002 | Semin. Oncol. | pmid:12520479 |